Page 176 - ADULT-ONSET ASTHMA PREDICTORS OF CLINICAL COURSE AND SEVERITY

ADULT-ONSET ASTHMA – PREDICTORS OF CLINICAL COURSE AND SEVERITY
20. Schleich FN, Chevremont A, Paulus V, Henket M, Manise M, Seidel L, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 2014; 44:97-108.
21. Zeiger RS, Schatz M, Li Q, Chen W, Khatry DB, Gossage D, et al. High blood eosinophil count is a risk factor for future asthma exacerba ons in adult persistent asthma. J Allergy Clin Immunol Pract 2014; 2:741-50.
22. Cowan DC, Taylor DR, Peterson LE, Cowan JO, Palmay R, Williamson A, et al. Biomarker-based asthma phenotypes of cor costeroid response. J Allergy Clin Immunol 2014.
23. van der Schee MP, Palmay R, Cowan JO, Taylor DR. Predic ng steroid responsiveness in pa ents with asthma using exhaled breath pro ling. Clin Exp Allergy 2013; 43:1217-25.
24. Hekking PP, Bel EH. Developing and emerging clinical asthma phenotypes. J Allergy Clin Immunol Pract 2014; 2:671-80; quiz 81.
25. Chung KF. Targe ng the interleukin pathway in the treatment of asthma. Lancet 2015; 386:1086-96.
26. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocor coid-sparing e ect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189-97.
27. uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 2016; 4:781-96.
28. Wagener AH, de Nijs SB, Lu er R, Sousa AR, Weersink EJ, Bel EH, et al. External valida on of blood eosinophils, FE(NO) and serum perios n as surrogates for sputum eosinophils in asthma. Thorax 2015; 70:115-20.
29. Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodru PG, Fahy JV. Measures of gene expression in sputum cells can iden fy TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol 2014; 133:388-94.
30. Fens N, van der Sluijs KF, van de Pol MA, Dijkhuis A, Smids BS, van der Zee JS, et al. Electronic nose iden es bronchoalveolar lavage uid eosinophils in asthma. Am J Respir Crit Care Med 2015; 191:1086-8.
31. Mukherjee M, Svenningsen S, Nair P. Glucocor osteroid subsensi vity and asthma severity. Curr Opin Pulm Med 2017; 23:78-88.
32. Ricciardolo FL, Sorbello V, Folino A, Gallo F, Massaglia GM, Favata G, et al. Iden ca on of IL-17F/ frequent exacerbator endotype in asthma. J Allergy Clin Immunol 2016.
33. Wood LG, Baines KJ, Fu J, Sco HA, Gibson PG. The neutrophilic in ammatory phenotype is associated with systemic in amma on in asthma. Chest 2012; 142:86-93.
34. Fu JJ, Baines KJ, Wood LG, Gibson PG. Systemic in amma on is associated with di eren al gene expression and airway neutrophilia in asthma. Omics 2013; 17:187-99.
35. Baines KJ, Backer V, Gibson PG, Powel H, Porsbjerg CM. Impaired lung func on is associated with systemic in amma on and macrophage ac va on. Eur Respir J 2015; 45:557-9.
36. Peters MC, McGrath KW, Hawkins GA, Has e AT, Levy BD, Israel E, et al. Plasma interleukin-6 concen- tra ons, metabolic dysfunc on, and asthma severity: a cross-sec onal analysis of two cohorts. Lancet Respir Med 2016; 4:574-84.
37. Nair P, Aziz-Ur-Rehman A, Radford K. Therapeu c implica ons of ‘neutrophilic asthma’. Curr Opin Pulm Med 2015; 21:33-8.
38. Brusselle GG, Vanders chele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for preven on of exacerba ons in severe asthma (AZISAST): a mul centre randomised double-blind placebo-controlled trial. Thorax 2013; 68:322-9.
39. Ronmark E, Lindberg A, Watson L, Lundback B. Outcome and severity of adult onset asthma - Report from the obstruc ve lung disease in northern Sweden studies (OLIN). Respiratory Medicine 2007; 101:2370-7.
174